The company witnesses strong growth across its India, Africa, and emerging markets businesses, while securing regulatory approval for the first AB-rated gVentolin in the U.S. market
Global specialty pipeline accelerates growth
The company’s shares of confidence were underlined by an upgraded 2026 outlook, with Merck now expecting annual net sales of up to €21.4 billion and EBITDA pre of as much as €6.1 billion
Net income more than doubled to 2.763 billion euros, while core earnings per share climbed 12.9 percent to 2.71 euros
Pan-India multidisciplinary program aims to improve coordinated care for patients with chronic kidney disease and heart failure
Lormalzi is the first and only once-monthly amyloid plaque-targeting therapy with clinical evidence
The company highlighted a series of strategic moves during the year, including the acquisition of WOKADINE, marking its entry into the Rs. 648 Cr Povidone Iodine market
The CDMO segment saw a 22% decline in Q4 due to a strong base in the prior year
Strong export-led growth and improved profitability as the company focuses on CNS drug development and global regulatory footprint
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
